Vanguard Capital Management
MXCT icon

Vanguard Capital Management’s MaxCyte MXCT Stock Holding History

Vanguard Capital Management’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.96M Buy
4,031,284
+49,468
+1% +$49.3K ﹤0.01% 3122
2026
Q1 		$2.8M Buy
+3,981,816
New +$3.72M ﹤0.01% 3258

Other funds holding MXCT

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $128M AUM
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management's MXCT Position: Q2 2026 in Review

Vanguard Capital Management increased its MaxCyte (MXCT) stake by 1.2% in Q2 2026, buying an estimated $49.3K and bringing the position to 4,031,284 shares worth $4.96M. The position accounts for ﹤0.01% of the portfolio, ranked #3122.

Vanguard Capital Management first reported a position in MXCT in Q1 2026 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • Vanguard Capital Management held 4,031,284 shares of MaxCyte worth $4.96M as of Q2 2026.
  • Vanguard Capital Management bought 49,468 MaxCyte shares in Q2 2026, an estimated $49.3K.
  • MaxCyte made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3122 holding.
  • Vanguard Capital Management first reported a position in MaxCyte in Q1 2026 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.